Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)
Massachusetts General Hospital
Summary
This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black/African ancestry and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostate cancer, characterization of the penetrance of specific mutations, and potentially identify new genetic risk mutations.
Description
Prostate cancer is the most common malignancy and the second leading cause of cancer-related deaths in American men. Prostate cancer has substantial inherited predisposition and men harboring specific genetic variants or a positive family history have been associated with an increased risk of developing prostate cancer. Men with specific genetic variants, such as pathogenic BRCA2 mutations, are at particularly greater risk of developing aggressive forms of prostate cancer and thus warrant undergoing careful screening for prostate cancer. However, the penetrance of many mutations in prostate ca…
Eligibility
- Age range
- 35–74 years
- Sex
- Male
- Healthy volunteers
- No
Inclusion Criteria: * Men 35-74 years old * No known diagnosis of prostate cancer * Life expectancy \>10 years * Meet cohort A, B, or C criteria * Cohort A: Documented pathogenic or likely pathogenic germline genetic mutation in a prostate cancer risk gene from a CLIA-certified laboratory (ATM, ATR, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, FANCA, GEN1, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53) * Cohort B: A strong family history suggestive of high genetic risk for prostate cancer with negative clinical genetic testing * Cohort C: Individuals who self-identify as Black Americ…
Interventions
- Diagnostic TestProstate cancer screening
Physical exam (digital rectal exam), prostate-specific antigen (PSA) and PSA derivatives, and multiparametric MRI of the prostate
Location
- Massachusetts General HospitalBoston, Massachusetts